Veracyte, Inc.
VCYTNASDAQHealthcare● Active
$47.27
$-1.46(-3.00%)
Market Cap$3.8B
P/E Ratio—
52W High$50.71
52W Low$22.61
Veracyte, Inc. (VCYT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VCYT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.52B | $0.45B | $0.36B | $0.30B | $0.22B |
| Cost of Revenue | $0.16B | $0.15B | $0.11B | $0.10B | $0.07B |
| Gross Profit | $0.36B | $0.30B | $0.25B | $0.19B | $0.15B |
| Gross Margin %(computed) | 69.62% | 66.88% | 68.73% | 65.74% | 66.11% |
| Operating Expenses | |||||
| R&D Expenses | $0.07B | $0.07B | $0.06B | $0.04B | $0.03B |
| G&A Expenses | $0.11B | $0.18B | $0.16B | $0.08B | $0.10B |
| Total Operating Expenses | $0.29B | $0.28B | $0.33B | $0.24B | $0.23B |
| Operating Income | $0.07B | $0.02B | ($0.09B) | ($0.04B) | ($0.08B) |
| Operating Margin %(computed) | 14.34% | 3.62% | -23.76% | -13.85% | -37.31% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.07B | $0.03B | ($0.08B) | ($0.04B) | ($0.08B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.00B | ($0.01B) |
| Net Income | $0.07B | $0.02B | ($0.07B) | ($0.04B) | ($0.08B) |
| Net Margin %(computed) | 12.83% | 5.41% | -20.61% | -12.33% | -34.42% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.84 | $0.32 | $-1.02 | $-0.51 | $-1.11 |
| Wtd Avg Shares | 0.08B | 0.08B | 0.07B | 0.07B | 0.07B |
| EBITDA | $0.09B | $0.05B | ($0.05B) | ($0.01B) | ($0.06B) |
| EBITDA Margin %(computed) | 17.33% | 11.04% | -13.68% | -2.35% | -27.42% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Veracyte, Inc. data
About Veracyte, Inc. (VCYT) Income Statement
Veracyte, Inc. (VCYT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VCYT reported revenue of $0.52B, gross profit of $0.36B (gross margin 69.62%), and net income of $0.07B — a net profit margin of 12.83%.
Frequently asked questions
VCYT · 4 questionsVeracyte, Inc. (VCYT) reported revenue of $0.52B for 2025, up 16.0% year-over-year.
VCYT revenueVCYT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08